Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-10-31T23:37:25.273Z Has data issue: false hasContentIssue false

Incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia or schizoaffective disorder

Published online by Cambridge University Press:  16 April 2020

R. Sanchez
Affiliation:
Bristol-Myers Squibb Company, Paris, France
E. Kim
Affiliation:
Bristol-Myers Squibb Company, Plainsboro, NJ, USA
J. Eudicone
Affiliation:
Bristol-Myers Squibb Company, Wallingford, CT, USA
A. Pikalov
Affiliation:
Otsuka America Pharmaceuticals Inc., Rockville, MD, USA
E. Vester-Blokland
Affiliation:
Bristol-Myers Squibb Company, Princeton, NJ, USA
D.D. Miller
Affiliation:
Department of Psychiatry Research, University of Iowa Carver College of Medicine, Iowa City, IA, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and aims:

Clinical trials suggest that patients receiving atypical antipsychotics are less likely to develop movement disorders than those receiving conventional antipsychotics. We determined incidence of treatment-emergent TD during long-term treatment of schizophrenia or schizoaffective disorder with aripiprazole or haloperidol.

Methods:

In a post hoc analysis of pooled data collected from two 52-week double-blind trials involving 1,294 patients treated either with aripiprazole 20-30mg/d (n=861) or haloperidol 5-10mg/d (n=433), treatment-emergent TD was identified based on Research Diagnostic Criteria (RDC) extracted from the Abnormal Involuntary Movement Scale (AIMS) (Schooler-Kane criteria).

Results:

In patients without baseline TD (n=1,177), the rate of new-onset TD at any time point following randomization was 5.09% for aripiprazole-treated patients and 11.76% for haloperidol-treated patients (p<0.0001). Using a stricter definition of RDC-defined TD on the last two study visits, new-onset TD was seen in 0.25% of aripiprazole-treated patients versus 4.09% of haloperidol-treated patients (p<0.0001), and was mild in 100% of aripiprazole-treated patients, and mild in 68.75% and moderate or severe in 31.25% of haloperidol-treated patients. Mean baseline to endpoint increase in AIMS score was significantly greater in haloperidol- versus aripiprazole-treated patients in both LOCF (n=1177, p=0.0001) and OC (n=427, p<0.0001) analyses.

Conclusions:

Aripiprazole is associated with a significantly reduced risk of new-onset tardive dyskinesia compared with haloperidol in patients with schizophrenia or schizoaffective disorder treated for up to 52 weeks. Aripiprazole's dopamine D2 partial agonist and/or serotonin 5HT2A antagonist receptor binding profile may contribute to this.

Type
Poster Session 1: Schizophrenia and Other Psychosis
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.